bamlanivimab monotherapy (n=163) vs. placebo (n=151)
randomized controlled trial
LY-CoV555
LY-CoV555 at a dose of 7000 mg as a single intravenous infusion over a 1-hour period
placebo
supportive care as background therapy, including the antiviral drug remdesivir and,when indicated, supplemental oxygen and glucocorticoids
COVID 19 hospitalized
double-blind
31 sites in US, Denmark, Singapore
Study stopped for futility (seven-category ordinal scale on day 5). As of April 2021, regulatory authorities recommend that bamlanivumab no longer be used because of the potential risk of treatment failure due to the circulation of resistant variants of SARS-CoV-2.